Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Advanced glycosylation end product CML as early diagnosis marker of myocardial ischemia reperfusion injury and application thereof

A technology of advanced glycation and reperfusion injury, applied in the field of reducing myocardial ischemia-reperfusion injury, early diagnosis markers of myocardial ischemia-reperfusion injury, and achieving the effect of reducing myocardial ischemia-reperfusion injury

Inactive Publication Date: 2018-09-07
ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the prior art, there is no report about the advanced glycation end product CML as an early diagnostic marker of myocardial ischemia-reperfusion injury and the application of Pyridorin to inhibit the formation of CML so as to alleviate myocardial ischemia-reperfusion injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Advanced glycosylation end product CML as early diagnosis marker of myocardial ischemia reperfusion injury and application thereof
  • Advanced glycosylation end product CML as early diagnosis marker of myocardial ischemia reperfusion injury and application thereof
  • Advanced glycosylation end product CML as early diagnosis marker of myocardial ischemia reperfusion injury and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1 Establishing a mouse model of ischemia-reperfusion injury and detecting the level of advanced glycation end product CML

[0039] Experimental materials: 7-8 weeks wild-type C57B / 6 mice, CML antibody (ab27684, abcam, USA), CML detection kit (OxiSelect TM Nε-(carboxymethyl)lysine (CML) Competitive ELISA Kit, CellBiolabs, USA)

[0040]Methods: 1) 7-8 weeks old wild-type C57B / 6 mice were taken, anesthetized with 2% isoflurane, opened the left chest cavity of the mice, ligated the anterior descending branch with 6-0 suture to cause myocardial ischemia, and loosened after 40 minutes. After the thread knot was opened, the myocardial tissue and peripheral blood of the mouse were taken 2 hours, 24 hours, and 48 hours after the thread knot was loosened to detect the CML level. 2) For the detection method of CML in peripheral blood, please refer to the instructions of the CML detection kit. 3) Myocardial tissue CML detection method: extract myocardial tissue protein, ...

Embodiment 2

[0042] Example 2 Effect of CML on cardiac function and infarct size in mice

[0043] Experimental materials: 7-8 weeks old wild-type C57B / 6 mice, CML reagent, Evans blue dye, TTC dye

[0044] Methods: 1) 7-8 weeks old wild-type C57B / 6 mice were taken, anesthetized with 2% isoflurane, opened the left chest cavity of the mice, ligated the anterior descending branch with 6-0 suture to cause myocardial ischemia, and loosened after 40 minutes. Open the thread knot, inject 0.1mg / kg CML locally with the myocardial tissue, and suture the chest cavity; 2) 24 hours later, use the VisualSonics VeVo 2100 imaging system to detect the mouse heart function; 3) 2% isoflurane anesthetize the mouse, open the chest cavity, Use 1% Evans blue dye to perfuse the mouse heart, remove the mouse heart, cut it into 4-5 pieces, put it into a petri dish filled with 1% TTC, incubate at 37 degrees for 30 minutes, in the asana The area of ​​myocardial infarction was observed under a microscope.

[0045] Re...

Embodiment 3

[0046] Example 3 Effects of Pyridorin on Cardiac Function and Infarct Size in Myocardial Ischemia-Reperfusion Injury Model Mice

[0047] Experimental materials: 6-7 weeks wild type C57B / 6 mice, pyridorin drug, Evans blue dye, TTC dye

[0048] Methods: 1) Take wild-type C57B / 6 mice at 6-7 weeks, add Pyridorin (1g / L) to their drinking water and feed them for a week, and use the above method to establish a myocardial ischemia-reperfusion model; 2) After 24 hours, , VisualSonics; VeVo2100 imaging system was used to detect the cardiac function of mice; 3) The infarct area of ​​mice was observed by the above method.

[0049] Results: Pyridorin can effectively improve the cardiac function and myocardial infarct size after ischemia-reperfusion injury in mice. (Fig. 5, 6)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an advanced glycosylation end product CML as an early diagnosis marker of myocardial ischemia reperfusion injury and application thereof, and particularly discloses adoption of CML as an early diagnosis marker of myocardial ischemia reperfusion injury, and application of Pyridorin in inhibiting production of CML so as to relieve myocardial ischemia reperfusion injury. According to the invention, verified in animal level, the advanced glycosylation end product CML is remarkably increased after myocardial ischemia reperfusion, and therefore, myocardial ischemia reperfusion injury can be diagnosed and predicated by detecting the level of the advanced glycosylation end product CML in the peripheral blood of a testee individual or a sample of an in vitro myocardial tissue. By applying an inhibitor Pyridorin, myocardial ischemia reperfusion injury can be effectively relieved, and Pyridorin can be used as an active component for resisting against myocardial ischemia reperfusion injury to be used for preparing medicine for treating myocardial ischemia reperfusion injury. The invention provides a new effective target for diagnosis and treatment of myocardial ischemia reperfusion injury.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to CML, an advanced glycation end product, as an early diagnostic marker for myocardial ischemia-reperfusion injury, and the use of Pyridorin to inhibit the generation of CML so as to alleviate myocardial ischemia-reperfusion injury. Background technique [0002] In recent years, with the advent of an aging society, the improvement of people's quality of life and the widespread prevalence of CVD risk factors, the incidence and mortality of CVD in my country have increased year by year. According to the latest "China Cardiovascular Disease Report" released by the National Cardiovascular Center, CVD deaths account for the first cause of death among urban and rural residents in my country, with 45.01% in rural areas and 42.61% in cities, higher than tumors and other systemic diseases ( figure 1 ). Among them, ischemic heart disease (IHD), especially coronary heart disease (CHD), i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68
CPCG01N33/68G01N2333/4704G01N2800/32
Inventor 葛均波杨继娥孙爱军张峰高旸曲亚男
Owner ZHONGSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com